AUT00206

Autifony Therapeutics Limited · Phase 1 active Small molecule

At a glance

Generic name	AUT00206
Sponsor	Autifony Therapeutics Limited
Modality	Small molecule
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Safety, Tolerability and Pharmacokinetics of AUT00206 in Patients With Schizophrenia, and Also Explores the Effects of AUT00206 on Relevant Central Biomarkers. (PHASE1)
A Study to Assess the pharmacoMRI Effects of AUT00206 in Healthy Males (PHASE1)
Safety, Blood Levels and Effects of AUT00206 (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

AUT00206 CI brief — competitive landscape report
AUT00206 updates RSS · CI watch RSS
Autifony Therapeutics Limited portfolio CI